Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

Yasmin Rosshandler, Ann Q. Shen, Jorge Cortes, Hanna Jean Khoury

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)419-424
Number of pages6
JournalExpert Review of Hematology
Issue number5
StatePublished - May 3 2016
Externally publishedYes


  • Chronic myeloid leukemia
  • omacetaxine mepesuccinate
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this